Mereo Biopharma Share Discussion Threads

[showmethemoneyhoney01] 13/1/2020 14:11

Good start on the Nasdeq. Currently at $2.85, up 35%

[showmethemoneyhoney01] 13/1/2020 14:01

Share price forecast from FT
The 2 analysts offering 12 month price targets for Mereo BioPharma Group PLC have a median target of 670.00, with a high estimate of 690.00 and a low estimate of 650.00. The median estimate represents a 1,930.30% increase from the last price of 33.00.
0.0
500.0
1.0k
High
1,990.9% 690.00
Med
1,930.3% 670.00
Low
1,869.7% 650.00

[shanur90] 13/1/2020 13:29

I don't get people who have banked and have to type and brag about how they banked just jog on with your money

[jackjackpaul] 13/1/2020 13:21

4 million now but also a free carry through phase two and three with all R&D costs paid for - with potential of up to 300 million payments along the way. Not to shabby T all considering this isn't even Mario's main compound.

[dave4545] 13/1/2020 13:19

cappick aka stocktracker

I boguht the 2 x 5000 on Friday trades 19/20

I also bought the 2500 at 34.9p and 35.1p and the 5000 at 36.4p

Nice profit, bit of luck with the Rns

If it was not for Invesco holding so many and selling down I'd have held out for more

[jackjackpaul] 13/1/2020 13:11

Directors were loading up at 60p levels 3 months ago... now only 45p after this transformational news

crazy

[showmethemoneyhoney01] 13/1/2020 13:05

$300m plus percentages of sublicensing revenues.

[iamgreat1] 13/1/2020 13:05

Wonder when the dump will start

[showmethemoneyhoney01] 13/1/2020 13:04

Additionally, Mereo will be eligible to receive up to $300 million in future clinical, regulatory and commercial milestones, tiered royalties ranging from the mid-single-digit to sub-teen percentages on global annual net sales of navicixizumab, as well as a negotiated percentage of sublicensing revenues from certain sublicensees.

"We believe Oncologie is expertly positioned to further advance navicixizumab through clinical development and towards potential commercialization," said Dr. Denise Scots-Knight, Chief Executive Officer of Mereo. "While we believe navicixizumab is an exciting oncology asset, we continue to focus our primary efforts on the development of our innovative rare disease portfolio including our lead product candidate setrusumab for the treatment of osteogenesis imperfecta, which continues to advance towards a pivotal Phase 3 pediatric study."

[jackjackpaul] 13/1/2020 13:00

Fact is deal is worth up to £300m... .. Current market cap is £35m.... Broker target is £7.20p.. Last year this was £1.90

Huge rerate coming here to over £1 over the coming days imo

[showmethemoneyhoney01] 13/1/2020 13:00

I have very high hopes for this company. They are working on multiple projects. Get just one decent sized one to commercialisation and this will be worth many multiples.

[dave4545] 13/1/2020 12:59

I see the long termers have arrived.

[leedslad001] 13/1/2020 12:58

never listen to anybody on BB boards do your own research and you won't go far wrong. BUY and tuck away for next 3 years

[shanur90] 13/1/2020 12:55

They will clear. Huge volume and going to tick upshortly. Plus Americans will open shortly.

[74tom] 13/1/2020 12:52

Invesco selling into the rise & have 18.98% to sell - on the watchlist for now.

[mcrudden] 13/1/2020 12:52

Huge news. Very nice for holders

[shanur90] 13/1/2020 12:50

Very good rns. Hopefully test recent highs.

[naim96aim] 13/1/2020 12:46

1 pound plus*

[naim96aim] 13/1/2020 12:46

Mahoooosive rns - wait till the yanks are up - £1+ coming imo.

[jackjackpaul] 13/1/2020 12:45

Broker target is £7.20p here also

[jackjackpaul] 13/1/2020 12:43

thats huge news for a £34m market cap company.. deal is global and worth up to £300M... thats 10x current market cap... Can see this heading to £1 levels over the coming days

[fund1] 13/1/2020 12:32

Well done nice when that happens. Should finish well into the 50s

[ny boy] 13/1/2020 12:29

This will race ahead at over 100mph soon, certainly a great opportunity to accumulate on the recent dip..now off to the races, a big stock for the new decade, dyor as usual!

Resistances: Resistance1: 47.23p. Resistance2: 61.75p